0 CHECKOUT

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015

  • ID: 3448674
  • September 2015
  • 337 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen, Inc.
  • Escape Therapeutics, Inc.
  • Jazz Pharmaceuticals Plc
  • MacroGenics, Inc.
  • REGiMMUNE Corporation
  • MORE

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015

Summary

The report ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015’, provides an overview of the Graft Versus Host Disease (GVHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Biogen, Inc.
  • Escape Therapeutics, Inc.
  • Jazz Pharmaceuticals Plc
  • MacroGenics, Inc.
  • REGiMMUNE Corporation
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Graft Versus Host Disease (GVHD) Overview

Therapeutics Development

Pipeline Products for Graft Versus Host Disease (GVHD) - Overview

Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis

Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies

Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes

Graft Versus Host Disease (GVHD) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Graft Versus Host Disease (GVHD) - Products under Development by Companies

Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

AbbVie Inc.

AbGenomics International, Inc.

Actelion Ltd

Adienne Pharma & Biotech

Alexion Pharmaceuticals, Inc.

Apceth GmbH & Co. KG

Athersys, Inc.

Bellicum Pharmaceuticals, Inc.

Bio-Cancer Treatment International Limited

Biogen, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Cell2B S.A.

CytoDyn Inc.

Dr. Falk Pharma GmbH

Enlivex Therapeutics Ltd

Escape Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Generon (Shanghai) Corporation Ltd.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

ImmuNext, Inc.

Immunomedics, Inc.

Jazz Pharmaceuticals Plc

Kadmon Corporation, LLC

Kamada Ltd.

Kiadis Pharma B.V.

Kymab Limited

MacroGenics, Inc.

Mesoblast Limited

Millennium Pharmaceuticals, Inc.

MSM Protein Technologies, Inc.

Neopharm Ltd.

Novartis AG

Omni Bio Pharmaceutical Inc.

Pharmicell Co., Ltd.

R-Tech Ueno, Ltd.

REGiMMUNE Corporation

Rigel Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Seattle Genetics, Inc.

Sigmoid Pharma Limited

Spherium Biomed S.L.

Targazyme, Inc.

Therapix Biosciences Ltd

Tobira Therapeutics, Inc.

Xenikos B.V.

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

abatacept - Drug Profile

AbGn-168H - Drug Profile

aldesleukin - Drug Profile

Alecmestencel-L - Drug Profile

Alpha-1 Antitrypsin - Drug Profile

alpha-1 proteinase inhibitor (human) - Drug Profile

ALXN-1007 - Drug Profile

anti-thymocyte globulin (rabbit) - Drug Profile

Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile

ApoCell - Drug Profile

ATIR-101 - Drug Profile

BCT-100 - Drug Profile

begelomab - Drug Profile

Biologics for Graft Versus Host Disease - Drug Profile

bortezomib - Drug Profile

BPX-501 - Drug Profile

brentuximab vedotin - Drug Profile

budesonide - Drug Profile

cannabidiol - Drug Profile

Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile

Cell Therapy for Graft Versus Host Disease - Drug Profile

Cell Therapy for Graft Versus Host Disease - Drug Profile

Cell Therapy for Graft Versus Host Disease - Drug Profile

Cell Therapy for Graft versus Host Disease - Drug Profile

Cell Therapy for Graft Versus Host Disease - Drug Profile

Cell Therapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile

cenicriviroc mesylate - Drug Profile

CLBS-03 - Drug Profile

CRCBT-080004 - Drug Profile

cyclosporine IR + cyclosporine CR - Drug Profile

CYP-001 - Drug Profile

defibrotide - Drug Profile

Drugs for Acute and Chronic GVHD - Drug Profile

erismodegib - Drug Profile

F-652 - Drug Profile

Fc-Alpha-1 Antitrypsin - Drug Profile

FcAAT-2 - Drug Profile

FcAAT-3 - Drug Profile

Ha-7 - Drug Profile

ibrutinib - Drug Profile

ImmuneSafe - Drug Profile

Immunocellgram for Graft Versus Host Disease - Drug Profile

IMO-8400 - Drug Profile

inolimomab - Drug Profile

IT-603 - Drug Profile

IT-901 - Drug Profile

KD-025 - Drug Profile

KY-1005 - Drug Profile

MesoStem - Drug Profile

MGD-010 - Drug Profile

milatuzumab - Drug Profile

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile

MSM-707 - Drug Profile

MultiStem - Drug Profile

natalizumab - Drug Profile

Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile

panobinostat - Drug Profile

ponesimod - Drug Profile

Preimplantation Factor - Drug Profile

PRO-140 - Drug Profile

Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease - Drug Profile

Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile

Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile

remestemcel-L - Drug Profile

RGI-2001 - Drug Profile

RO-2959 - Drug Profile

RTU-009 - Drug Profile

Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile

Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile

Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile

Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile

SP-12008 - Drug Profile

Substance X - Drug Profile

T-Guard - Drug Profile

TZ-101 - Drug Profile

Graft Versus Host Disease (GVHD) - Recent Pipeline Updates

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015

Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Biogen, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Caladrius Biosciences, Inc. , H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by CytoDyn Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma B.V., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2015

Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H2 2015

Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2015

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2015

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2015

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2015

Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015

Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
AbGenomics International, Inc.
Actelion Ltd
Adienne Pharma & Biotech
Alexion Pharmaceuticals, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
Biogen, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Cell2B S.A.
CytoDyn Inc.
Dr. Falk Pharma GmbH
Enlivex Therapeutics Ltd
Escape Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Generon (Shanghai) Corporation Ltd.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
ImmuNext, Inc.
Immunomedics, Inc.
Jazz Pharmaceuticals Plc
Kadmon Corporation, LLC
Kamada Ltd.
Kiadis Pharma B.V.
Kymab Limited
MacroGenics, Inc.
Mesoblast Limited
Millennium Pharmaceuticals, Inc.
MSM Protein Technologies, Inc.
Neopharm Ltd.
Novartis AG
Omni Bio Pharmaceutical Inc.
Pharmicell Co., Ltd.
R-Tech Ueno, Ltd.
REGiMMUNE Corporation
Rigel Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Seattle Genetics, Inc.
Sigmoid Pharma Limited
Spherium Biomed S.L.
Targazyme, Inc.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Xenikos B.V.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare